Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
2008
Effects of Aplidin on Multiple Myeloma
Sample size: 30
publication
Evidence: high
Author Information
Author(s): Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K
Primary Institution: Vrije Universiteit Brussel
Hypothesis
Does Aplidin have antitumour and antiangiogenic effects in multiple myeloma models?
Conclusion
Aplidin is well tolerated and shows significant antitumour and antiangiogenic effects in multiple myeloma.
Supporting Evidence
- Aplidin reduced serum paraprotein concentration by 42%.
- Aplidin decreased bone marrow invasion by 35%.
- Aplidin inhibited angiogenesis to basal values.
- Aplidin treatment prolonged survival of mice from 42.9 days to 51.5 days.
Takeaway
Aplidin is a medicine that helps fight a type of blood cancer called multiple myeloma by stopping cancer cells from growing and helping to kill them.
Methodology
The study used in vitro and in vivo experiments on murine models to assess the effects of Aplidin on myeloma cells.
Participant Demographics
C57Bl/KaLwRij mice, aged 6-10 weeks.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI=6.87–9.17 nM
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website